Mode
Text Size
Log in / Sign up
N/A N=225 Randomized Double-blind Treatment

A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement

Subjects Desiring Lip Augmentation

Enrolled (actual)
225
Serious AEs
2.4%
Results posted
Dec 2016
Primary outcome: Primary: Change From Baseline in Evaluating Investigator's Assessment of Lip Fullness on a 5-Point Scale — 1.2; 1.1; 1.1; 1.0 Scores on a Scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
JUVEDERM VOLBELLA® XC (Device); Restylane-L® (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Allergan
Primary completion
Aug 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Evaluating Investigator's Assessment of Lip Fullness on a 5-Point Scale
1.2; 1.1; 1.1; 1.0
SECONDARY
Percentage of Subjects in the JUVEDERM VOLBELLA® XC Treatment Arm With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)
65.9
SECONDARY
Change From Baseline in Subject Satisfaction With Lips on the Lip Module of the FACE-Q Questionnaire
37.6; 29.0

Summary

This is a multicenter, double-blind, randomized, controlled study of the safety and effectiveness of JUVÉDERM VOLBELLA® XC Injectable Gel versus Restylane-L® for lip and perioral enhancement.

Eligibility Criteria

Inclusion Criteria

  • 22 years of age or older
  • Has a score of minimal, mild, or moderate on the LFS2, as agreed upon by the Treating and Evaluating Investigators, and desires at least 1 point of correction for one or both lips
  • For treatment of perioral lines, has a POLSS score of severe or moderate as agreed upon by the Treating and Evaluating Investigators (all subjects are eligible for treatment in the vermilion body, oral commissures, vermilion border, Cupid's bow, and philtral columns)

Exclusion Criteria

  • Has lip tattoos, piercings, facial hair, or scars that would interfere with visualization of the lips and perioral area for the effectiveness assessments
  • Has dentures or any device covering all or part of the upper palate, and/or severe malocclusion or dentofacial or maxillofacial deformities as judged by the Treating Investigator
  • Has undergone oral surgery (e.g., tooth extraction, orthodontia, or implantation) within 6 weeks before enrollment or is planning to undergo any of these procedures during the study
  • Has ever undergone facial plastic surgery or received permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face or neck, or is planning to be implanted with any of these products during the study
  • Has undergone semipermanent dermal filler treatment (e.g., calcium hydroxylapatite, poly-L-lactic acid) in the lower face (below the orbital rim) within 24 months before enrollment or is planning to undergo such treatment during the study
  • Has undergone temporary dermal filler treatment (e.g., hyaluronic acid or collagen) in the lower face (below the orbital rim) within 12 months before enrollment or is planning to undergo such treatment during the study
  • Has undergone mesotherapy or cosmetic resurfacing (laser, photo-modulation, intense pulsed light, radiofrequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) anywhere in the face or neck, or Botulinum toxin injections in the lower face (below the orbital rim) within 6 months before enrollment or is planning to undergo any of these procedures during the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01998581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search